Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial

NCT00577122 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT00577122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00577122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2007
Completion date
December 31, 2011
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor-negative breast cancer, progesterone receptor-negative breast cancer, recurrent breast cancer, stage iv breast cancer